ABSI - Company ID 0001672688
Absci Corp trades as ABSI and has a market capitalization of $1.79 B, making it the #2230 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.80M, down 38.2% from the prior year and net income of -$115.18M. This page tracks Absci Corp through 336 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Absci Corp's revenue declined from $4.78M to $2.80M, a compound annual decline rate of 10.1%. Net profit margin compressed from -300.3% to -4113.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| SCHEDULE 13D/A | - | 2026-04-14 |
| SCHEDULE 13D/A | - | 2026-03-26 |
2026 Jefferies Global Healthcare Conference (New York, NY)
Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” ther
Absci management is scheduled to participate in a fireside chat on Thursday, April 16 th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.
Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline
The largest companies sharing Absci Corp's SEC industry classification (services-commercial physical & biological research).
Absci Corp (ABSI) has a market capitalization of $1.79 B as of 2026-07-09, ranking #2230 among US-listed companies.
Absci Corp reported revenue of $2.80M for fiscal year 2025, a decrease of 38.2% year over year.
In its latest fiscal year Absci Corp reported a net loss of $115.18M.